Clinical Trial Update: IL-1 Inhibition in Early TNBC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating IL-1 inhibition in early-stage triple-negative breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: University Health Network, Toronto | Conditions: Early Stage Triple Negative ER Low Breast Cancer | Phase 2 | Status: WITHDRAWN